[1]
Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001; 5: 378-87.
[2]
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
[3]
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366(9493): 1267-78.
[4]
Kitzmiller JP, Mikulik EB, Dauki AM, Murkheriee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharm Genomics Pers Med 2016; 9: 97-106.
[6]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 21; 6: e1000097.
[7]
Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 2004; 62: 273-8.
[8]
Bei WJ, Chen SQ, Li HL, et al. Comparing common doses (double-dose vs. usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography. Medicine 2017; 96: e7501.
[9]
Giacoppo D, Gargiulo G, Buccheri S, et al. Preventive strategies for contrast-induced acute kidney Injury in patients undergoing percutaneous coronary procedures. Circ Cardiovasc Interv 2017; 10: e004383.
[10]
Zhang MM, Lv QZ, Li XY. Drug effects and clinical investigations for contrast-induced nephropathy after coronary angiography or percutaneous coronary intervention in patients with diabetes. Am J Ther 2017; 24: e423-30.
[11]
Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008; 101: 279-85.
[12]
Zhao J-L, Yang Y-J, Zhang Y-H, You S-J, Wu Y-J, Gao R-L. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2008; 126: 435-6.
[13]
Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-9.
[14]
Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. Am J Cardiol 2011; 108: 1-7.
[15]
Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98: 59-77.
[16]
Özhan H, Erden I, Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010; 61: 711-4.
[17]
Zhang W, Zhang Y, Li CW, Jones P, Wang C, Fan Y. Effect of statins on COPD: A meta-analysis of randomized controlled trials. Chest 2017; 152: 1159-68.
[18]
Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD. The impact of statin drug use on all-cause mortality in patients with COPD: A population-based cohort study. Chest 2017; 152: 486-93.
[19]
Chogtu B, Kuriachan S, Magazine R, et al. A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Indian J Pharmacol 2016; 48: 503-8.
[20]
Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
[21]
Rossi A, Inciardi RM, Temporelli PL, et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther 2017; 44: 16-23.
[22]
Ajmera M, Shen C, Sambamoorthi U. Association between statin medications and COPD-specific outcomes: A real-world observational study. Drugs Real World Outcomes 2016; 4: 9-19.
[23]
Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530-5.
[24]
Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013; 126: 598-606.
[25]
Chou CY, Chou YC, Chou YJ, Yang YF, Huang N. Statin use and incident dementia: a nationwide cohort study of Taiwan. Int J Cardiol 2014; 173: 305-10.
[26]
Smith KB, Kang P, Sabbagh MN. The effect of statins on rate of cognitive decline in mild cognitive impairment. Alzheimers Dement (N Y) 2017; 3: 149-56.
[27]
Benito-León J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 2010; 21: 95-102.
[28]
Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the research database. BMJ 2010; 340: 2197.
[29]
Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson’s disease: A meta-analysis. Behav Brain Res 2016; 309: 29-34.
[30]
Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case-control study. J Clin Neurosci 2008; 15: 1272-3.
[31]
Orlando A, Thomas C, Carrick M, Slone DS, Mains CW, Bar-Or D. Statin discontinuation and mortality in an older adult population with traumatic brain injury: A four-year, multi-center, observational cohort study. Injury 2016; 48: 1040-6.
[32]
Farzanegan GR, Derakhshan N, Khalili H, Ghaffarpasand F, Paydar S. Effects of atorvastatin on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury; a randomized double-blind placebo-controlled clinical trial. J Clin Neurosci 2017; 44: 143-7.
[33]
Neilson SJ, See AA, King NK. Effect of prior statin use on outcome after severe traumatic brain injury in a South-East Asian population. Brain Inj 2016; 30: 993-8.
[34]
Schneider EB, Efron DT, MacKenzie EJ, Rivara FP, Nathens AB, Jurkovich GJ. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma 2011; 71: 815-9.
[35]
Xiong Y, Wong A, Cavalieri M, et al. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities. Neurotherapeutics 2014; 11: 606-11.
[36]
Chan DYC, Chan DTM, Sun TFD, Ng SCP, Wong GKC, Poon WS. The use of atorvastatin for chronic subdural hematoma: a retrospective cohort comparison study. Br J Neurosurg 2017; 31: 72-7.
[37]
King NK, Tay VK, Allen JC, Ang BT. Prior statin use has no effect on survival after intracerebral hemorrhage in a multiethnic Asian patient cohort. Acta Neurochir Suppl 2012; 114: 343-6.
[38]
Wee HY, Ho CH, Liang FW, et al. Increased risk of new-onset depression in patients with traumatic brain injury and hyperlipidemia: the important role of statin medications. J Clin Psychiatry 2016; 77: 505-11.
[39]
Chodick G, Heymann AD, Flash S, Kokia E, Shalev V. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol 2010; 20: 136-42.
[40]
Hermans M, Ahn S, Rousseau M. Statin therapy and cataract in type 2 diabetes. Diabetes Metab 2011; 37: 139-43.
[41]
Casula M, Soranna D, Corrao G, Merlino L, Catapano AL, Tragni E. Statin use and risk of cataract: a nested case-control study within a healthcare database. Atherosclerosis 2016; 251: 153-8.
[42]
Erie JC, Pueringer MR, Brue SM, Chamberlain AM, Hodge DO. Statin use and incident cataract surgery: a case-control study. Ophthalmic Epidemiol 2016; 23: 40-5.
[43]
Yu S, Chu Y, Li G, Ren L, Zhang Q, Wu L. Statin use and the risk of cataracts: a systematic review and metaanalysis. J Am Heart Assoc 2017; 6: e004180.
[44]
Lash TL, Riis AH, Ostenfeld EB, et al. Associations of statin use with colorectal cancer recurrence and mortality in a Danish cohort. Am J Epidemiol 2017; 186: 679-87.
[45]
Ling Y, Yang L, Huang H, et al. Prognostic significance of statin use in colorectal cancer: a systematic review and meta-analysis. Medicine 2015; 94: e908.
[46]
Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008; 19: 767-74.
[47]
Platz EA, Tangen CM, Goodman PJ, et al. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol 2014; 192: 379-84.
[48]
Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 2015; 51: 725-33.
[49]
Hutchinson J, Marignol L. Clinical potential of statins in prostate cancer radiation therapy. Anticancer Res 2017; 37: 5363-72.
[50]
Larsen SB, Dehlendorff C, Skriver C, et al. Post-diagnosis statin use and mortality in Danish patients with prostate cancer. J Clin Oncol 2017; 35: 3290-7.
[51]
Stensland K, McBride RB, Leapman M, Hobbs A, Jazayeri SB, Samadi DB. Preoperative statin use associated with lower PSA but similar prostate size and histopathologic outcomes: Implications for active surveillance? Urol J 2017; 14: 3064-70.
[52]
Allott EH, Howard LE, Vidal AC, et al. Statin use, serum lipids, and prostate inflammation in men with a negative prostate biopsy: Results from the REDUCE trial. Cancer Prev Res (Phila) 2017; 10: 319-26.
[53]
Lochhead P, and Chan T. Statins and colorectal cancer. Clin Gastroenterol Hepatol 2013; 11: 109-14.
[54]
Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-8.
[55]
Shrestha P, Poudel DR, Pathak R, et al. Effect of statins on the mortality of bacteremic patients: A systematic review and meta-analysis of clinical trials. N Am J Med Sci 2016; 8: 250.
[56]
López-Cortés LE, Gálvez-Acebal J, Del Toro MD, et al. Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study. PLoS One 2013; 8: e82958.
[57]
Caffrey AR, Timbrook TT, Noh E, et al. Evidence to support continuation of statin therapy in patients with staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2017; 61: e02228.
[58]
Dinglas VD, Hopkins RO, Wozniak AW, et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax 2016; 7: 401-10.
[59]
Gui Q, Yang Y, Zhang J. Effects of statins on the development of sepsis and organ dysfunction in hospitalized older patients in China. Braz J Infect Dis 2017; 21: 255-62.
[60]
Yu Y, Zhu C, Liu C, Gao Y. Effect of prior atorvastatin treatment on the frequency of hospital acquired pneumonia and evolution of biomarkers in patients with acute ischemic stroke: a multicenter prospective study. BioMed Res Int 2017; 2017: 5642704.
[61]
Doshi SM, Kulkarni PA, Liao JM, Rueda AM, Musher DM. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013; 345: 173-7.
[62]
Novack V, Eisinger M, Frenkel A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009; 35: 1255-60.
[63]
Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker. Intensive Care Med 2006; 32: 160-4.
[64]
Morse LR, Nguyen N, Battaglino RA, et al. Wheelchair use and lipophilic statin medications may influence bone loss in chronic spinal cord injury: findings from the FRASCI-bone loss study. Osteoporos Int 2016; 27: 3503-11.
[65]
Stillman MD, Aston CE, Rabadi MH. Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis. Spinal Cord 2016; 54: 298-302.
[66]
Aghazadeh J, Motlagh PS, Salehpour F, et al. Effects of atorvastatin in patients with acute spinal cord injury. Asian Spine J 2017; 11: 903-7.
[67]
Wu X, Xu XM. RhoA/Rho kinase in spinal cord injury. Neural Regen Res 2016; 11: 23-37.
